Data presented at CROI 2021 show that the COVID-19 pandemic has disrupted health systems around the world, affecting diagnosis and treatment of HIV and other diseases, especially in low- and middle-income countries.
My take on data from several Kenyan studies presented at CROI 2021, including analyses of STI incidence among girls and young women and investigations into factors associated with and strategies for promoting improved PrEP uptake.
CROI 2021 provided more data on ARV-associated weight gain and longer-term data on injectable ART. Here are my key takeaways for healthcare professionals.
Data on long-acting ART continued to dominate the presentations at CROI 2021. Here are my thoughts on the practicalities of potentially integrating these new drugs into my practice in Canada.
My picks for interesting HIV treatment data presented at CROI 2021 include 2 studies performed in Spain, one comparing the efficacy of fixed-dose boosted PI combination ART vs second-generation integrase inhibitors and one investigating treatment options for newly diagnosed patients with advanced HIV.
My pick for data presented at CROI 2021 is a study comparing post-ART weight gain in people with HIV in Latin America vs Latinx people with HIV in the United States and Canada.